93
Participants
Start Date
June 30, 2012
Primary Completion Date
June 30, 2015
Study Completion Date
October 31, 2015
Pegylated interferon alfa 2b
Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
Ribavirin
Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
Oslo/Akershus University hospitals, Oslo
St Vincent's Hospital, Sydney
Hunter Pharmacotherapy, Newcastle
Nepean Hospital, Penrith
Alfred Hospital, Melbourne
Koda Bern/Poliklinik fur Infektiologe, Bern
Basel Zentrum fur Suchtmedizin, Basel
Royal Adelaide Hospital, Adelaide
Praxiszentrum Im Tal (PIT), Munich
ZNA Stuivenberg / MSOC Free Clinic, Antwerp
Ziekenhuis Oost Limburg / MSOC Limburg, Genk
Vancouver ID Research and Care Centre Society, Vancouver
East Toronto Hepatitis C Program, Toronto
CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal
ARUD, Poliklinik Zokl 1, Zurich
East London Foundation NHS Trust, London
Nottingham University Hospitals NHS Trust, Nottingham
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Kirby Institute
OTHER_GOV